Agios Pharmaceuticals (NASDAQ:AGIO) Given New $37.00 Price Target at SVB Leerink

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) had its target price hoisted by SVB Leerink from $33.00 to $37.00 in a report issued on Friday morning, MarketBeat.com reports. SVB Leerink currently has an outperform rating on the biopharmaceutical company’s stock.

Separately, The Goldman Sachs Group dropped their target price on Agios Pharmaceuticals from $20.00 to $16.00 and set a sell rating on the stock in a research report on Tuesday, May 24th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $51.14.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $29.74 on Friday. Agios Pharmaceuticals has a 52-week low of $16.75 and a 52-week high of $50.98. The business’s 50-day moving average price is $21.47 and its 200 day moving average price is $25.43.

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.10. The company had revenue of $5.58 million for the quarter, compared to analysts’ expectations of $2.86 million. The business’s quarterly revenue was up 5482.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.36) EPS. On average, equities analysts forecast that Agios Pharmaceuticals will post -7.04 EPS for the current year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Agios Pharmaceuticals by 2.1% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 20,942 shares of the biopharmaceutical company’s stock worth $610,000 after acquiring an additional 427 shares in the last quarter. ETF Managers Group LLC boosted its stake in shares of Agios Pharmaceuticals by 5.0% during the 4th quarter. ETF Managers Group LLC now owns 13,233 shares of the biopharmaceutical company’s stock worth $444,000 after acquiring an additional 630 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of Agios Pharmaceuticals by 37.9% during the 1st quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 805 shares in the last quarter. Allianz Asset Management GmbH boosted its stake in shares of Agios Pharmaceuticals by 1.8% during the 4th quarter. Allianz Asset Management GmbH now owns 50,500 shares of the biopharmaceutical company’s stock worth $1,666,000 after acquiring an additional 870 shares in the last quarter. Finally, Point72 Hong Kong Ltd boosted its stake in shares of Agios Pharmaceuticals by 214.6% during the 4th quarter. Point72 Hong Kong Ltd now owns 1,513 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 1,032 shares in the last quarter.

About Agios Pharmaceuticals

(Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Further Reading

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.